Biofilm formation by ESBL-producing uropathogenic E. coli
DOI:
https://doi.org/10.37285/ijpsn.2022.15.4.8Abstract
Introduction: E. coli is considered to be the leading cause of urinary tract infections. (UTIs) and is responsible for both community acquired and hospital acquired UTIs. The ability of this bacterium to form biofilm on various devices like catheters plays an important role in progression of the disease. Biofilm production in extended spectrum beta lactamases (ESBLs) producing organisms provides a favourable environment for the exchange of resistance genes and may also facilitate widespread dissemination.
Methods: The urine samples were collected from the suspected cases of urinary tract infections and were cultured on cystine lactose electrolyte deficient (CLED) agar plates to isolate the desired UPEC strains. All the isolated E. coli strains were subjected to ESBL detection by double disk approximation method and to biofilm formation by tissue culture plate method of biofilm detection. All the results were statistically analysed using k2 test with p value at <0.05 level of significance.
Results: Out of all the gram negative bacilli isolated from urine samples, E. coli alone accounted for 90% of the isolates. Of all the UPEC isolates subjected to ESBL detection 50% of the strains turned out to be the ESBL producers and 35% of the strains showed biofilm formation.
Conclusion:
- The majority of the work in literature sites the data samples collected from indoor patients, where these isolates coli strains which produced ESBLs were mainly a strong biofilm former as compared to non-ESBL producer strains.
- In this study in spite of all the coli strains being outpatient isolates still the correlation between ESBL production and biofilm formation holds true.
- We found a significant correlation between biofilm formation and ESBL production. The detection of ESBL production and biofilm formation pattern will help in development of newer and more effective treatment.
Downloads
Metrics
Keywords:
Extended-spectrum beta-lactamases, Urinary tract infections, Biofilm, E. coli.
Downloads
Published
How to Cite
Issue
Section
References
Boll EJ, Struve C, Boisen N, Olesen B, Stahlhut SG, Krogfelt KA. ((2013). Role of entero-aggregative Escherichia coli virulence factors in uropathogenesis. Infect Immune. 81:1164-1171.
Brooun A, Liu S, Lewis K. (2000) A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 44(3):640-6.
Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF, Melton DM, et al. Adherence of coagulase-negative Staphylococci to plastic tissue culture plates: A quantitative model for the adherence of Staphylococci to medical devices. J Clin Microbiol 22:996-1006
Clinical and Laboratory Standards Institute. (2014) Performance Standards for Antimicrobial Susceptiblity Testing; Twenty-fourth Informational Supplement. CLSI Document M100-S24. Vol. 33. Wayne, PA, USA: Clinical and Laboratory Standards Institute.
Costerton JW, Stewart PS, Greenberg EP. (1999) Bacterial biofilms: a common cause of persistent infections. Science, 284(5418):1318-22.
Dhakal BK, Kulesus RR, Mulvey MA (2008). Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli. Eur J Clin Invest 38: 2–11.
Fatima S, Prasanthi K, Nagamani K. (2015) Comparative evaluation of biofilm production in Multidrug resistant and sensitive Gram negative clinical isolates. Int J Curr Microbiol Appl Sci. 4(6):918–26.
Hedlund M, Duan RD, Nilsson A, Svensson M, Karpman D, Svanborg C, et al. (2001) Fimbriae, transmembrane signaling, and cell activation. J Infect Dis 183 Suppl 1:S47-50.
Hussain JH, Sharma A, Jaggi T, Mishra B, Thakur A, Dogra V, et al. (2017). Epidemiology of biofilm formation by Gram-negative bacilli in patients with urinary tract infection in a tertiary care hospital. Int J Heal Allied Sci. 6:15–9.
Lee JH, Subhadra B, Son YJ, Kim DH, Park HS, Kim JM, et al. (2016) Phylogenetic group distributions, virulence factors and antimicrobial resistance properties of uropathogenic Escherichia coli strains isolated from patients with urinary tract infections in South Korea. Lett Appl Microbiol. 62(1):84-90.
O’Hanley P. (1996). Prospects for urinary tract infection vaccines. Urinary tract infection: molecular pathogenesis and clinical management. 405–425.
Paterson DL and Bonomo RA. (2005). Extended spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 18: 657-686.
Peirano G, Mulvey GL, Armstrong GD, Pitout JD. (2013). Virulence potential and adherence properties of Escherichia coli that produce CTX-M and NDM lactamases. J Med Microbial. 62:525-530.
Ramesh N, Sumathi CS, Balasubramanian V, Palaniappan KR, Kannan VR. (2008). Urinary tract infection and antimicrobial susceptibility pattern of extended spectrum beta lactamase producing clinical isolates. Adv Biol Res. 2:78–82.
Sivick KE, Mobley HL. (2010). Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun. 78(2):568–85.
Stamm WE, Norrby SR. (2001). Urinary tract infections: disease panorama and challenges. J Infect Dis 183: s1-s4.
Subramanian P, Umadevi S, Kumar S, Stephen S. (2012). Determination of correlation between biofilm and extended spectrum β lactamases producers of Enterobacteriaceae. Scho Res J. 2:2–6.
Totsika M, Moriel DG, Idris A, Rogers BA, Wurpel DJ, Phan MD, et al. (2012). Uropathogenic Escherichia coli mediated urinary tract infection. Curr Drug Targets 13: 1386-1399
Villa L, Pezzella C, Tosini F, Visca P, Petrucca A, and Carattoli A. (2000). Multiple-antibiotic resistance mediated by structurally related IncL/M plasmids carrying an extended spectrum beta-lactamase gene and class 1 integron. Antimicrob Agents Chemother. 44:2911-2914
Wilson ML, Gaido L. (2004). Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis. 38(8):1150–8.
